# Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder

- Link: https://www.thailand-business-news.com/pr-news/ribo-submits-european-clinical-trial-application-for-a-novel-dual-targeting-sirna-sr122-for-mixed-and-severe-dyslipidemia-further-strengthening-its-footprint-in-the-area-of-lipid-disorder
- Published: 2026-11-10T08:00:00+07:00
- Author: PR Newswire

|   |

SUZHOU, China and MÖLNDAL, Sweden, Nov. 10, 2026 /PRNewswire/ — Suzhou Ribo Life
Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively 
referred to as "Ribo") announced the submission of a Phase Ⅰ Clinical Trial Application(
CTA) in EU for SR122, a dual GalNAc conjugated siRNA therapeutic being developed
for the treatment of dyslipidemia, including severe hypertriglyceridemia (sHTG) 
and mixed dyslipidemia.

As Ribo progresses the Phase II clinical studies of RBD5044 — its core lipid asset
and the world’s second-most advanced ApoC3-targeting siRNA — in Europe and China,
this filing marks a further upgrade to its lipid pipeline strategy and a key step
in solidifying its leading position in lipid disorders.

SR122 simultaneously targets ApoC3 and PCSK9, two clinically validated pathways 
that play complementary roles in lipid metabolism. By addressing both triglyceride-
rich lipoproteins and low-density lipoprotein cholesterol (LDL-C), SR122 has the
potential to provide a differentiated treatment approach with durable improvements
across multiple lipid parameters and cardiometabolic risk factors.

Dyslipidemia remains a major global health challenge and a key driver of cardiovascular
disease, the leading cause of death worldwide. Patients with mixed dyslipidemia 
often continue to face substantial residual cardiovascular risk despite currently
available lipid-lowering therapies, while individuals with severe hypertriglyceridemia
are also at increased risk of acute pancreatitis.

The Phase 1 clinical trial is a randomized, placebo-controlled study designed to
evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously
administered SR122 in healthy participants. The study will provide the first clinical
evaluation of the dual targeting SR122 approach in humans and generate key data 
to support further development.

"The simultaneous knockdown of ApoC3 and PCSK9 provides superior synergy in reducing
overwhelming lipid risk in severe hypertriglyceridemia and represent a step change
in patient risk management through inhibition of complementary mechanisms. The results
of the Phase Ⅰ trial will be guiding the further advancement through clinical development
in the intended target population." said Dr. Anders Gabrielsen, Chief Medical Officer
of Ribo.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder ](https://www.prnasia.com/story/archive/5092505_AE92505_0?rand=184833)